Tirzepatide
Prescription OnlyOverview
Tirzepatide is a dual GLP-1/GIP receptor agonist. The branded product Mounjaro has received TGA approval in Australia. The compounding pathway for tirzepatide is currently under review, and grey market supply has been increasing.
Australian Scheduling
Schedule 4 (Prescription Only). Mounjaro is TGA-approved and ARTG-listed. Compounding pathway is under active regulatory review. The TGA is monitoring the grey market supply closely.
Access Pathway
Available through telehealth providers and compounding pharmacies, though fewer providers offer it compared to semaglutide. The compounding pathway may face restrictions. Grey market availability is increasing but carries significant risk.
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.